MARK2 and cancer: Sorafenib can block the activation of MAPK/extracellular-signal-regulated kinase (ERK) signaling and inhibit cancer cell proliferation by inhibiting the expression of subtypes of serine/threonine kinases Raf, RAF-1 and B-Raf [45].